Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Insulin; related peptides
Reexamination Certificate
2007-11-20
2007-11-20
Bragdon, Kathleen Kerr (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Insulin; related peptides
C530S300000, C424S278100
Reexamination Certificate
active
10894999
ABSTRACT:
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5187154 (1993-02-01), Phillips et al.
patent: 5264372 (1993-11-01), Beaumont et al.
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5686511 (1997-11-01), Bobo
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6858576 (2005-02-01), Young et al.
patent: 6902744 (2005-06-01), Kolterman et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 199731732 (1997-06-01), None
patent: WO 9011296 (1990-04-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9318786 (1993-09-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 95/07098 (1995-03-01), None
patent: WO 96/06626 (1996-03-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/19698 (1998-05-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 99/07404 (1999-02-01), None
Chantry et al. (1991) Cross-reactivity of amylin with calcitonin-gene-related peptide binding sites in rat liver and skeletal muscle membranes. Biochem. J. vol. 277 (Pt 1), pp. 139-143.
Dhillo et al. (2003) Paraventricular nucleus administration of calcitonin gene-related peptide inhibits food intake and stimulates the hypothalamo-pituitary-adrenal axis. Endocrinology. vol. 144, No. 4, pp. 1420-1425.
Buffer solution (updated 2007) Wikipedia, “Commone buffer compounds used in biology”, http://en.wikipedia.org./□□wiki/Buffer—solution, p. 1.
Turton et al., Nature, vol. 379, pp. 69-72, 1996.
Goldstone et al, FEBS Letters, vol. 415, pp. 134-138, 1997.
Vandermeers et al, European Journal of Biochemistry, 1987, vol. 164, pp. 321-327.
Strandberg et al (Acta Radiologica, 1988, vol. 29, pp. 49-52).
GenBank Accession No. CAA24759, Feb. 9, 1999.
Adelhorst, K., et al, “Structure-activity studies of glucagon-like peptide-1 (GLP-1),”J. Bio Chem269(9):6275-8 (1994).
Bartlett, et al, “Inhibition of Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs,”Bioorg. Chem. 14:356-377 (1986).
Bhavsar, “Inhibition of gastric emptying and of food intake appear to be independently controlled in rodents,”Soc. Neurosci. Abst. 21:460 (188.8)(1995).
Cohen, et al,The Pico Tag Method; A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989).
D'Alessio et al. “Elimination of the Action of glucagon-like Peptide 1 Causes an Impairment of glucose tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38, 1996.
Eissele et al. “Rat Gastric somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci., 55:629-34, 1994.
Eng et al. “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom”,J. Biol. Chem., 267:7402-05, 1992.
Eng et al. “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265:20259-62, 1990.
Fehmann et al. “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),”Peptides15 (3): 453-6, 1994.
Ferguson et al. “Cell-Surface Anchoring of Proteins Via Glycosylphosphatidylinositol Structures”,Annu. Rev. Biochem. 57:285-320 (1988).
Goke et al. “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting -Cells”,J. Biol. Chem., 268:19650-55, 1993.
Kodama, J., et al, “Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,”Diabetes Care13(11):1109-1111 (1990).
Kolligs, et al, “Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide,”Diabetes44:16-19 (1995).
Leibel, R.L., et al, “Changes in Energy Expenditure Resulting from Altered Body Weight,”New England Journal of Medicine332(10):621-628 (1995).
Lithell, et al, “Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,”J. Cardiovasc. Pharmacol. 15 (Supp 5):S46-S52 (1990).
Malhotra et al. “Exendin-4, a new peptide fromHeloderma suspectumvenom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini”,Regulatory Peptides, 41:149-56, 1992.
Montrose-Rafizadeh et al. “Structure-function Analysis of Exendin-4 / GLP-1 Analogs”,Diabetes, 45(Suppl. 2):152A, 1996.
O'Halloran et al. “Glucagon-like peptide-1 (7-36)-NH2: a physiological inhibitor of gastric acid secretion in man,”J. Endocrinol126 (1): 169-73 (1990).
Ørskov et al. “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable”,Diabetes, 42:658-61 (1993).
Pelleymounter, et al, “Effects of the obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science269:540-543 (1995).
Raufman et al. “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas”,J. Biol. Chem. 267:21432-37 (1992).
Raufman et al. “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem. 266:2897-902 (1991).
Schepp et al. “Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,”Eur. J. Pharm. 269:183-91 (1994).
Schjoldager et al. “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig Dis Sci34 (5): 703-8 (1989).
Singh et al. “Use of1251-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,”Regul. Pept. 53:47-59 (1994).
Thorens, “Expression cloning of the pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1,”Proc. Natl. Acad. Sci. USA89:8641-45 (1992).
Thorens, et al. “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes42 (11): 1678-82 (1993).
Turton, et al, “A role for glucagon-like peptide-1 in the central regulation of feeding,”Nature379:69-72 (1996).
Veale, P.R., et al, “The presence of islet amyloid polypeptide/calcitonin gen-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens,”European Journal of Pharmacology262:133-141 (1994).
Wang et al. “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest., 95:417-21 (1995).
Watson, N., et al, “Effects of captopril on glucose tolerance in elderly patients with congestive cardiac failure,”Current
Beeley Nigel Robert Arnold
Bhavsar Sunil
Gedulin Bronislava
Prickett Kathryn S.
Young Andrew
Amylin Pharmaceuticals Inc.
Bragdon Kathleen Kerr
Liu Samuel Wei
LandOfFree
Pharmaceutical compositions containing exendins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing exendins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing exendins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3815920